Biocon secures 10-year Pertuzumab supply contract in Brazil under PDP program
Biocon Ltd · Pharmaceuticals & Biotechnology
What the filing says
- Biocon partners with Bahiafarma and Bionovis for exclusive 10-year supply of Pertuzumab in Brazil
- Contract grants 100% allocation under Brazil's PDP, covering ~70% of public healthcare demand
- Product to undergo phased local manufacturing in Brazil, with milestone payments and revenue share
Why it's rated notable: The partnership agreement is signed and the 10-year allocation is granted, but the filing gives no contract value or revenue estimate, so the size against annual revenue of ₹17,321 crore cannot be judged and the level is medium.
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other order win filings this fortnight
- Welspun Corp secures ₹5,500 crore order for coated pipes in US natural gas project
- Jyoti Structures Ltd receives ₹689.93 Cr order for 765kV DC Pachchham-Saykha line
- Asian Energy Services Limited informs execution of Revenue Sharing Contract for DSF Bid Round-IV
- Waaree Renewable updates Solar PV EPC contracts, aggregate capacity now 800 MWac
- KEC International secures new orders worth Rs. 1,006 crores on October 23, 2026
- Sterlite Technologies Limited approves unaudited Q2 and H1 FY27 results on October 23, 2026
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.